Oculis Holding AG (NASDAQ:OCS) Stock Has Consensus Target Price of $39.44 According to Brokerages

by · The Markets Daily

Oculis Holding AG (NASDAQ:OCS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $39.44.

Several equities analysts have recently commented on OCS shares. JPMorgan Chase & Co. decreased their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. HC Wainwright increased their price target on Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Finally, Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th.

Read Our Latest Report on Oculis

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of OCS. Braidwell LP acquired a new stake in shares of Oculis during the second quarter valued at about $11,570,000. Bank of America Corp DE raised its stake in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after acquiring an additional 5,813 shares during the period. Squarepoint Ops LLC lifted its holdings in shares of Oculis by 326.4% in the 2nd quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after acquiring an additional 47,158 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Oculis in the 1st quarter worth approximately $776,000. Finally, Himension Capital Singapore PTE. LTD. purchased a new position in shares of Oculis during the 1st quarter worth approximately $503,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Trading Down 5.5%

OCS opened at $7.88 on Tuesday. The stock has a market capitalization of $456.91 million, a PE ratio of -4.53 and a beta of 0.62. Oculis has a one year low of $7.85 and a one year high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The business’s 50 day moving average price is $11.15 and its 200 day moving average price is $16.91.

Oculis (NASDAQ:OCS – Get Free Report) last posted its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, equities research analysts expect that Oculis will post -2.01 EPS for the current year.

About Oculis

(Get Free Report)

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.

Further Reading